~~<i id='26D6262E2C'><strike id='26D6262E2C'><tt id='26D6262E2C'><pre id='26D6262E2C'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：fashion 2025-09-27 13:39:03 Page View：6

STAT Q&A — Paul Matteis (right), in 2017 with then-colleagues Seamus Fernandez (far left) Geoffrey Porges. Alex Hogan/STAT

NEW YORK — Is biotech having a renaissance in neuroscience? Can we solve the placebo effect? And what’s going to happen next year?

Paul Matteis, co-head of biotech research at Stifel, sat down with STAT at the firm’s annual health care conference here to field those questions and opine on how management teams can walk the delicate balance between hype and sandbagging. This transcript has been edited for length and clarity.

One thing I’ve been hearing lately is that biotech has entered a sort of renaissance in neuroscience. Do you agree with that?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bernie brings in new pharma CEOs to talk drug prices
Next article： Supreme Court strikes down use of affirmative action

explore

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

WASHINGTON--TheSupremeCourtwillreviewarulingstrikingdownadomesticviolencefederalgunban.

Unique patient identifier: Experts argue the benefits, pitfalls

Therehasbeenlong-standingdebateintheUSoverwhethertoimplementauniquepatientidentifiersystem.EvanVucci

Trump demands the U.S. pay no more for drugs than other countries … again

EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

Cue Health, Covid

AdobeInanabruptchangeofcoursefromplansearlierinthemonth,at-hometestmakerCueHealthislayingoffallofits